Skip to main content

Renal Pelvis and Ureter Cancer Clinical Trials

Review the renal pelvis and ureter cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 34

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Status: Active
Location: 469 locations
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) after Surgery to Remove all Known Sites of Kidney Cancer
Status: Active
Location: 399 locations
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Status: Active
Location: 16 locations
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Status: Active
Location: 16 locations
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Status: Active
Location: 10 locations
Neoadjuvant Enfortumab Vedotin for the Treatment of Patients with High-Grade Urothelial Cancer of the Upper Urinary Tract
Status: Active
Location: 8 locations
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Status: Active
Location: 21 locations
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 8 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Status: Active
Location: 9 locations
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Status: Active
Location: 6 locations
Sacituzumab Govitecan, Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Location: 5 locations
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Location: 7 locations
Locally Ablative Therapy for the Treatment of Oligo-progressive Prostate Cancer, Urinary Tract Cancer or Kidney Cancer, LAYOVER Trial
Status: Active
Location: 4 locations
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Status: Active
Location: 4 locations
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Status: Active
Location: 4 locations
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Status: Active
Location: 4 locations
Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with High Grade Upper Tract Urothelial Cancer who are not Candidates for, or Refuse, Nephroureterectomy
Status: Active
Location: 2 locations
Study of DF1001 in Patients with Advanced Solid Tumors
Status: Active
Location: 3 locations
Nephroureterectomy with and without Lymph Node Dissection for the Treatment of Upper Tract Urothelial Cancer
Status: Active
Location: 2 locations
Neoadjuvant Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with Upper Tract Urothelial Cancer, NEPTUNE Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Therapeutic Plasma Exchange with Enfortumab Vedotin and Pembrolizumab for the Treatment of Metastatic Refractory Bladder and Urinary Tract Cancers, RECIPE-B1 Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Adjuvant Sacituzumab Govitecan and Nivolumab for the Treatment of Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York